Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ophthalix Inc Appoints Dr. Gil Ben-Menachem As Chief Executive Officer
Ophthalix Inc announced that it has appointed Dr. Gil Ben-Menachem as Chief Executive Officer effective January 1, 2013.
Latest Developments for Ophthalix Inc
- Ophthalix Inc Announces CEO Change-Form 8-K
- OphthaliX Inc. Completes Preclinical Studies Showing Efficacy Of CF101 for Treatment Of Anterior Uveitis
- Denali Concrete Management Inc Announces Completion Of Reverse Acquisition By Can-Fite BioPharma Ltd.; Acquires EyeFite Ltd.; Closes $6 Million Private Placement
Latest Key Developments in Biotechnology
- Bioxyne Ltd Announces Termination Of Proposed Acquisition Of Vitality Devices Pty Ltd
- Repros Therapeutics Inc Announces That FDA Recommends Running Phase 2b Trial Of Proellex-V In Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
- Norda ASA Plans Delisting from Oslo Stock Exchange
- Stemline Therapeutics Inc Announces Closing Of $60 Million Public Offering Of Common Stock
- Share this
- Link this
- Digg this
Follow Reuters